Results 1 to 10 of about 1,730,683 (109)

Characterizing Tumor Thrombus Arising from Non–Clear Cell Renal Cell Carcinoma [PDF]

open access: yesEuropean Urology Open Science, 2022
Background: Renal cell carcinoma (RCC) can exhibit a unique vascular tropism that enables tumor thrombus extension into the inferior vena cava (IVC). While most RCC subtypes that form tumor thrombi are of clear cell (cc) histology, non–clear cell (ncc ...
Matthew J. Rabinowitz   +10 more
doaj   +2 more sources

Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature [PDF]

open access: yesCurrent Oncology, 2023
Non-clear cell renal cell carcinoma (nccRCC) is an entity comprised of a heterogeneous constellation of RCC subtypes. Genomic profiling has broadened our understanding of molecular pathogenic mechanisms unique to individual nccRCC subtypes.
Alexius John   +2 more
doaj   +2 more sources

The role of immunotherapy in non-clear cell renal cell carcinoma [PDF]

open access: yesFrontiers in Oncology, 2023
The category of non-clear cell renal cell carcinoma (nccRCC) includes several clinically, histologically, and molecularly diverse entities. Traditionally, they comprise type 1 and type 2 papillary, chromophobe, unclassified, and other histologies ...
Carla Climent   +12 more
doaj   +2 more sources

Integrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell Carcinoma [PDF]

open access: yesEuropean Urology Open Science
Background and objective: Previous germline studies on renal cell carcinoma (RCC) have usually pooled clear and non–clear cell RCCs and have not adequately accounted for population stratification, which might have led to an inaccurate estimation of ...
Seung Hun Han   +15 more
doaj   +2 more sources

Recent progress in non-clear cell renal cell carcinoma: biology and therapeutic strategies [PDF]

open access: yesTherapeutic Advances in Medical Oncology
Non-clear cell renal cell carcinomas (nccRCC) comprise a heterogeneous group of rare malignancies, accounting for approximately 20% of all kidney cancers.
Ahmet Yildirim   +6 more
doaj   +2 more sources

The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma [PDF]

open access: yesTherapeutic Advances in Urology
Renal cell carcinoma (RCC) is the most common type of kidney cancer and is divided into two distinct subtypes, clear cell renal cell carcinoma (ccRCC) and non-clear cell renal cell carcinoma (nccRCC).
Priyanka Naik   +5 more
doaj   +2 more sources

Identification of novel biomarkers to distinguish clear cell and non-clear cell renal cell carcinoma using bioinformatics and machine learning. [PDF]

open access: yesPLoS ONE
Renal cell carcinoma (RCC), accounting for 90% of all kidney cancer, is categorized into clear cell RCC (ccRCC) and non-clear cell RCC (non-ccRCC) for treatment based on the current NCCN Guidelines.
Chanita Panwoon   +3 more
doaj   +2 more sources

Efficacy and safety of combination immunotherapy for treating advanced non-clear cell renal cell carcinoma: A multicenter retrospective study in Japan [PDF]

open access: yesScientific Reports
This study aimed to evaluate the outcomes of patients with advanced renal cell carcinoma (aRCC) who were histologically diagnosed with non-clear cell carcinoma (nccRCC) and received combination immunotherapy.
Koji Iinuma   +12 more
doaj   +2 more sources

Current perspectives on systemic therapy for metastatic non-clear cell renal cell carcinoma [PDF]

open access: yesCellR4, 2020
The improvements in the knowledge of the underlying biology of renal cell carcinoma (RCC) has led to consider this disease as a group of different entities characterized by their pathological phenotype, and the particular features exhibited in their ...
J. González, G. Ciancio
doaj   +1 more source

Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma

open access: yesCancer Treatment and Research Communications, 2020
The treatment landscape for renal cell cancer (RCC) has evolved tremendously over the last two decades. Treatment algorithms have shifted from the highly toxic drugs with marginal benefit to better tolerated and more effective targeted therapy drugs. The
Shuchi Gulati   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy